###begin article-title 0
###xml 11 17 11 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
Functional ENTPD1 Polymorphisms in African Americans With Diabetes and End-Stage Renal Disease
###end article-title 0
###begin title 1
OBJECTIVE
###end title 1
###begin p 2
###xml 30 36 30 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 168 174 168 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 104 109 <span type="species:ncbi:10090">mouse</span>
###xml 149 154 <span type="species:ncbi:9606">human</span>
The vascular ectonucleotidase ENTPD1 protects against renal injury and modulates glucose homeostasis in mouse models. We sought to determine whether human variation in ENTPD1 influences predisposition to diabetes or diabetic nephropathy.
###end p 2
###begin title 3
RESEARCH DESIGN AND METHODS
###end title 3
###begin p 4
###xml 12 18 12 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 294 300 294 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 317 323 317 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 377 383 377 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 430 435 430 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">db/db</italic>
###xml 243 248 <span type="species:ncbi:9606">human</span>
###xml 398 403 <span type="species:ncbi:10090">mouse</span>
We analyzed ENTPD1 single nucleotide polymorphisms (SNPs) in 363 African American control subjects, 380 subjects with type 2 diabetes and end-stage renal disease (DM-ESRD), and 326 subjects with ESRD unrelated to diabetes (non-DM-ESRD). Using human cell lines, we correlated disease-associated ENTPD1 haplotypes with ENTPD1 gene expression. Finally, we studied consequences of ENTPD1 deletion in a mouse model of type 2 diabetes (db/db).
###end p 4
###begin title 5
RESULTS
###end title 5
###begin p 6
###xml 9 15 9 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 82 83 82 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 178 179 178 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 223 229 223 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 302 308 302 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 379 385 379 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 423 429 423 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 517 523 517 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 642 647 642 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">db/db</italic>
###xml 724 730 724 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 256 261 <span type="species:ncbi:9606">human</span>
###xml 391 395 <span type="species:ncbi:10090">mice</span>
###xml 404 408 <span type="species:ncbi:10090">mice</span>
###xml 565 569 <span type="species:ncbi:10090">mice</span>
###xml 648 652 <span type="species:ncbi:10090">mice</span>
###xml 736 740 <span type="species:ncbi:10090">mice</span>
A common ENTPD1 two-SNP haplotype was associated with increased risk for DM-ESRD (P = 0.0027), and an uncommon four-SNP haplotype was associated with protection against DM-ESRD (P = 0.004). These haplotypes correlated with ENTPD1 gene expression levels in human cell lines in vitro. Subjects with high ENTPD1-expressing haplotypes were enriched in the DM-ESRD group. By crossing ENTPD1-null mice with db mice, we show that ENTPD1 deletion has prominent effects on metabolic syndrome traits. Specifically, deletion of ENTPD1 lowered glucose levels in control (db/-) mice with one functional leptin receptor and dramatically lowered weights in db/db mice with no functional leptin receptors. Similar effects were seen in aged ENTPD1-null mice with normal leptin receptors.
###end p 6
###begin title 7
CONCLUSIONS
###end title 7
###begin p 8
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 205 211 205 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 136 141 <span type="species:ncbi:9606">human</span>
###xml 165 170 <span type="species:ncbi:10090">mouse</span>
ENTPD1 polymorphisms appear to influence susceptibility to type 2 diabetes and/or diabetic nephropathy in African Americans. Studies in human cell lines and in vivo mouse data support a potential role for ENTPD1 genetic variation in susceptibility to type 2 diabetes.
###end p 8
###begin p 9
###xml 178 179 178 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 305 306 305 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 307 308 307 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
Diabetes and its complications are enormous sources of mortality, morbidity, and cost in the U.S. African Americans are especially prone to diabetes and diabetic kidney disease (1). Genetic variation plays a major role in susceptibility to both development of diabetes and onset of diabetic renal injury (2,3). Finding genes responsible for this predisposition to disease could help predict who may be at high risk and also identify important pathways involved in disease pathogenesis.
###end p 9
###begin p 10
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 22 26 22 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CD39</italic>
###xml 162 163 162 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 199 205 199 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 312 318 312 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 405 406 405 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 406 406 406 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6"/>
###xml 407 408 407 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 411 417 411 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 498 499 498 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 500 501 500 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 518 524 518 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 619 620 619 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 655 657 655 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 504 508 <span type="species:ncbi:10090">Mice</span>
###xml 584 588 <span type="species:ncbi:10090">mice</span>
ENTPD1, also known as CD39, is an ectonucleotidase that hydrolyzes ATP and ADP to AMP, initiating an enzymatic cascade that leads to the generation of adenosine (4). By regulating nucleotide levels, ENTPD1 controls the activity of both purinergic receptors (P2X and P2Y) and downstream adenosine (P1) receptors. ENTPD1 is widely expressed, particularly in blood vessels and on cells of the immune system (5-7). ENTPD1 is present in glomeruli, afferent arterioles, and larger vessels of the kidney (8,9). Mice null for ENTPD1 sustained markedly more severe renal injury than wild-type mice in models of type 1 diabetes (9) and ischemia reperfusion injury (10).
###end p 10
###begin p 11
###xml 141 143 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 285 287 285 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 387 393 387 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 494 500 494 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 562 564 562 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 609 615 609 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 698 703 698 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENPP1</italic>
###xml 706 708 706 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 724 730 724 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 96 101 <span type="species:ncbi:9606">human</span>
###xml 506 510 <span type="species:ncbi:10090">mice</span>
###xml 690 696 <span type="species:ncbi:9606">humans</span>
###xml 767 773 <span type="species:ncbi:9606">humans</span>
Previously, a locus for susceptibility to diabetic and nondiabetic renal disease was located on human chromosome 10q24 in African Americans (11). Subsequently, others have also found loci in this chromosomal region associated with renal dysfunction in Caucasians with type 2 diabetes (12). It appears likely that one or more genes with effects on nephropathy are located in this region. ENTPD1 is located close to the linkage peak in both of these studies. More recently, we have reported that ENTPD1-null mice also exhibit abnormalities of glucose homeostasis (13). The close functional relationship between ENTPD1 and another ectonucleotidase that influences metabolic syndrome traits in humans, ENPP1, (14) suggests that ENTPD1 could affect glucose homeostasis in humans as well.
###end p 11
###begin p 12
###xml 34 40 34 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 181 187 181 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 566 571 566 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">db/db</italic>
###xml 587 593 587 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 698 704 698 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 757 763 757 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 224 232 <span type="species:ncbi:9606">patients</span>
###xml 268 276 <span type="species:ncbi:9606">patients</span>
###xml 341 349 <span type="species:ncbi:9606">patients</span>
###xml 481 486 <span type="species:ncbi:9606">human</span>
###xml 516 521 <span type="species:ncbi:10090">mouse</span>
###xml 613 618 <span type="species:ncbi:9606">human</span>
###xml 684 688 <span type="species:ncbi:10090">mice</span>
###xml 737 743 <span type="species:ncbi:9606">humans</span>
To determine whether variation in ENTPD1 might influence the development of diabetes or diabetic renal disease, we tested the frequency of single nucleotide polymorphisms (SNPs) in ENTPD1 in three groups of African American patients: 363 healthy control subjects, 326 patients with nondiabetic end-stage renal disease (non-DM-ESRD), and 380 patients with ESRD caused by type 2 diabetes (DM-ESRD). We support these genetic association results with functional studies in vitro using human cell lines and in vivo using mouse models with nonfunctional leptin receptors (db/db). We show that ENTPD1 gene expression in human cell lines correlates with the disease-associated genotypes, and mice null for ENTPD1 share metabolic phenotypes with humans who have low ENTPD1-expressing genotypes.
###end p 12
###begin title 13
RESEARCH DESIGN AND METHODS
###end title 13
###begin p 14
###xml 71 73 71 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 74 76 74 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 947 948 947 948 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</italic>
###xml 1010 1011 1010 1011 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 455 463 <span type="species:ncbi:9606">patients</span>
###xml 590 598 <span type="species:ncbi:9606">patients</span>
###xml 751 759 <span type="species:ncbi:9606">patients</span>
###xml 808 816 <span type="species:ncbi:9606">patients</span>
###xml 926 934 <span type="species:ncbi:9606">patients</span>
###xml 1162 1170 <span type="species:ncbi:9606">patients</span>
###xml 1214 1222 <span type="species:ncbi:9606">Patients</span>
Collection of control and case subjects has been described previously (15,16). Briefly, all subjects were recruited in North Carolina, South Carolina, Georgia, Virginia, or Tennessee, and all were born in one of these five southeastern states. A total of 363 unrelated African American control subjects were recruited through community screening events, all without a history of type 2 diabetes or renal disease. A total of 380 unrelated African American patients with type 2 diabetes and ESRD were recruited (DM-ESRD group) from dialysis clinics. A total of 326 unrelated African American patients with ESRD but without a history of diabetes (non-DM-ESRD) were also recruited from dialysis clinics. A single investigator (B.I.F.) classified all ESRD patients into DM-ESRD or non-DM-ESRD groups. Non-DM-ESRD patients included those with hypertension-associated ESRD or primary glomerular diseases. The DM-ESRD groups included patients with either 1) diabetes and histologic evidence of diabetic nephropathy or 2) with diabetes >/=5 years before the initiation of renal replacement therapy and either diabetic retinopathy or proteinuria >500 mg per 24 h. DM-ESRD patients had no other known cause of renal disease. Patients with renal cystic diseases, hereditary nephritis, or ESRD related to urologic disease were all excluded from analysis.
###end p 14
###begin title 15
Genotyping.
###end title 15
###begin p 16
###xml 239 245 237 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 305 311 303 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 399 401 397 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
A total of 18 SNPs tagging 80% of the known SNPs in the Yoruba (YRI) Hapmap population were selected using the program Tagger (). Tag SNPs all had minor allele frequency of >/=5%. rs3793744, the only common nonsynonymous coding variant in ENTPD1, was force inserted in SNP selection. Tag SNPs spanned the ENTPD1 gene on chromosome 10 from 97.504 to 97.613 Mb. We used a Sequenom MassArray platform (17) for genotyping.
###end p 16
###begin title 17
Genetic analysis.
###end title 17
###begin p 18
###xml 118 119 118 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
SNPs with call rates <96% were excluded from analysis. All SNPs were in conformation with Hardy-Weinburg equilibrium (P < 0.05) in control subjects. Determination of haploblock structures and associations were performed using Haploview (). Haplotypes with frequency >1% were included in the analysis. Permutation testing for haplotype associations was performed using Haploview software at 10,000 permutations.
###end p 18
###begin title 19
In vitro ENTPD1 expression studies.
###end title 19
###begin p 20
###xml 202 203 202 203 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 620 626 619 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 780 786 779 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 11 29 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 225 231 <span type="species:ncbi:9913">bovine</span>
Genotyped, Epstein-Barr virus-transformed lymphoblasts from the YRI HapMap () collection and Perlegen () African American panel were used for analysis. Cells were grown in RPMI-1640 media with 2 mmol/l l-glutamine, 15% fetal bovine serum, penicillin-streptomycin mix, and 10 mmol/l Hepes buffer. Cells were seeded at 200,000 per ml and harvested 24-48 h later in log-phase growth. Then, mRNA was isolated using RNeasy (Qiagen) according to the manufacturer's instructions. A total of 0.5 mug of mRNA was reversed transcribed to cDNA using the Taqman Reverse Transcription Kit (Applied Biosystems). Probe-primer sets for ENTPD1 and the 18S ribosomal subunit (loading control) were obtained from Applied Biosystems. Real-time PCR was performed on an Applied Biosystems 7700 system. ENTPD1 mRNA expression was normalized using 18S expression.
###end p 20
###begin p 21
###xml 358 363 <span type="species:ncbi:10090">mouse</span>
###xml 406 410 <span type="species:ncbi:9925">goat</span>
###xml 416 421 <span type="species:ncbi:10090">mouse</span>
For protein isolation, cells were washed twice with ice-cold PBS and then lysed in an NP-40-based buffer with protease inhibitors (Roche mini-tabs). A total of 40 mug of protein were separated on a gradient gel under nonreducing condtions and transferred to polyvinylidene fluoride paper (Millipore) using a semidry transfer apparatus. For ENTPD1, we used a mouse monoclonal antibody (BU-61; Ancell) and a goat anti-mouse secondary antibody (Pierce). We used anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody (Ambion) as a loading control. Band density was quantified with a Kodak ImageStation 2000M, and protein level was expressed as a ratio of ENTPD1 to GAPDH.
###end p 21
###begin title 22
In silico, expanded ENTPD1 expression studies.
###end title 22
###begin p 23
###xml 25 31 25 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 232 233 232 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 245 246 245 246 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
For YRI HapMap subjects, ENTPD1 gene expression levels were downloaded from (). Methods for the generation of this data are described by Stranger et al. (18). Genotypes were obtained from . Statistics were performed using Student's t test on log2-transformed data.
###end p 23
###begin title 24
Enzyme activity.
###end title 24
###begin p 25
###xml 262 264 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 322 324 321 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 117 126 <span type="species:ncbi:64457">Malachite</span>
A total of 250,000 lymphocytes were harvested in log-phase growth. ATPase and ADPase activity were determined with a Malachite Green assay for phosphate production as described previously using 200 mumol/l nucleotide as the substrate during a 10-min incubation (19). Tetramisole was used to inhibit alkaline phosphatases (19).
###end p 25
###begin title 26
Animal studies.
###end title 26
###begin p 27
###xml 259 262 259 262 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 348 353 348 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">db/db</italic>
###xml 380 386 380 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 455 461 455 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 461 464 461 464 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 4 9 <span type="species:ncbi:10090">mouse</span>
###xml 127 131 <span type="species:ncbi:10090">Mice</span>
###xml 338 342 <span type="species:ncbi:10090">mice</span>
###xml 465 469 <span type="species:ncbi:10090">mice</span>
All mouse studies were done with institutional animal care and use committee approval at Beth Israel Deaconess Medical Center. Mice in all four db groups originated from crossing db/- heterozygote breeders on a C57/BL6 background from Jackson Labs with ENTPD1-/- breeders backcrossed more than six times on a C57/BL6 background. Diabetic mice were db/db offspring with or without ENTPD1, and db/- offspring were used as controls. In the aging study, male ENTPD1-/- mice backcrossed more than six times onto a C57/BL6 background were compared with age- and strain-matched C57/BL6 wild-type controls.
###end p 27
###begin title 28
Animal phenotyping.
###end title 28
###begin p 29
###xml 348 351 348 351 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p.m</sc>
Albuminuria was quantified using an albumin-to-creatinine ratio. Albumin was measured using the Albuwell-M Kit from Exocell, and creatinine was measured using the Creatinine Companion from Exocell. Blood glucose was measured using a One Touch Ultra 2 glucometer (Lifescan). For the db-based studies, nonfasting glucose levels were measured at 3:00 p.m. For the non-db studies (aging), glucose levels were measured after an 8-h daytime fast.
###end p 29
###begin p 30
###xml 282 283 282 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 20 25 <span type="species:ncbi:10090">mouse</span>
For histopathology, mouse kidney tissue was fixed in 10% buffered formalin and embedded in paraffin then cut into 3-micron sections and stained with PAS stain. Glomerular area was calculated using Spot Imaging software. The glomerular sclerosis index has been described previously (9).
###end p 30
###begin title 31
RESULTS
###end title 31
###begin p 32
###xml 108 114 108 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 320 347 320 347 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">research design and methods</sc>
Using a set of markers chosen with the program Tagger, we genotyped 18 SNPs (minor allele frequency >5%) in ENTPD1 that were predicted to cover 80% of the known SNPs in the Yoruba (YRI) Hapmap population. Seventeen of 18 SNPs passed quality standards and conformed to Hardy-Weinburg equilibrium criteria as described in research design and methods above. These 17 SNPs tagged 79% of YRI HapMap SNPs.
###end p 32
###begin p 33
###xml 24 30 24 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 89 90 89 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 144 151 144 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 269 270 269 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Location of SNPs in the ENTPD1 gene, minor allele frequency of each SNP, and uncorrected P values in the populations in this study are shown in Table 1. When control subjects and subjects with non-DM-ESRD were compared, one SNP (rs6584026) showed nominal significance (P = 0.027). Comparing control subjects and subjects with DM-ESRD revealed two SNPS (rs12763743 and rs3897983) that were nominally significant (0.041 and 0.037, respectively).
###end p 33
###begin p 34
SNP analysis
###end p 34
###begin p 35
Individual SNP results for the association study comparing African American control subjects with type 2 diabetic ESRD and nondiabetoc ESRD. *rs3176894 did not meet quality control criteria.
###end p 35
###begin p 36
###xml 6 7 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
daggerP < 0.05 (boldface). When the odds ratio is >1, the minor allele is the risk allele; when the odds ratio is <1, the minor allele is the protective allele. MAF, minor allele frequency.
###end p 36
###begin p 37
###xml 438 439 438 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 450 451 450 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 632 639 632 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
We considered the possibility that the two nominally significant SNPs for DM-ESRD might have additive effects. We used the two significant SNPs discovered in the DM-ESRD population to form a two-SNP haplotype for further analysis. Three common combinations accounted for all subjects tested (AG = 82.9%, AA = 10.8%, and TG = 6.3%). The most common haplotype (AG) appeared to confer increased risk of diabetes and/or diabetic nephropathy (P = 0.0027, P = 0.009 after permutation; odds ratio 1.51) compared with the other two haplotypes, which were both nominally associated with protection from diabetes and/or diabetic nephropathy (Table 2). We refer to the AG haplotype as the two-SNP risk haplotype, and the combined group of AA and TG haplotypes as the two-SNP protective haplotypes. No difference was seen with respect to these two-SNP risk or protective haplotypes when comparing control subjects with non-DM-ESRD subjects.
###end p 37
###begin p 38
Haplotypes
###end p 38
###begin p 39
Association of DM-ESRD with two-SNP haplotypes consisting of the two nominally significant SNPs rs12763743 and rs3897983. The AG haplotype is referred to as the two-SNP risk haplotype, and the AA and TG haplotypes are referred to as the two-SNP protective haplotypes. Association of DM-ESRD with four-SNP haplotypes consisting of rs4918972, rs10748648, rs1342790, and rs3793744. The GAGA haplotype is referred to as the four-SNP protective haplotype.
###end p 39
###begin p 40
###xml 277 278 277 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 468 475 468 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 510 511 510 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
A broader, unbiased haplotype analysis using all successfully genotyped SNPs showed that 16 of the SNPs fell into a single haplotype block defining 10 haplotypes with frequency >1%. One haplotype was associated with protection against diabetes and/or diabetic nephropathy with P = 0.004 (odds ratio 0.34). This statistical significance of this protective haplotype remained unchanged when reduced to four SNPs (rs4918972, rs10748648, rs1342790, and rs3793744; GAGA in Table 2). After permutation analysis, the P value remained significant at 0.017. The GAGA haplotype is referred to as the four-SNP protective haplotype. This protective haplotype included the uncommon variant rs3793744, a coding SNP in exon 7 causing a valine to isoleucine substitution. No association was seen for this haplotype when comparing control subjects to non-DM-ESRD subjects.
###end p 40
###begin p 41
###xml 474 475 474 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 580 581 580 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 849 850 849 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1031 1032 1031 1032 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
We made several additional comparisons to help define whether our haplotypes were associated with diabetes or diabetic nephropathy. First, we compared healthy control subjects with all ESRD subjects (both DM-ESRD and non-DM-ESRD) and found much weaker associations for both the two-SNP and four-SNP haplotypes (supplementary Table 1 [available in an online appendix at ]). Then we compared non-DM-ESRD with DM-ESRD subjects: the two-SNP (AG) risk haplotype remained robust (P = 0.0038, odds ratio 1.53), while the four-SNP (GAGA) protective haplotype lost some statistical power (P = 0.024), though the odds ratio was unchanged (odds ratio 0.37) when non-ESRD subjects were substituted for control subjects. We also pooled healthy control subjects and non-DM-ESRD subjects into a nondiabetic group and compared them with DM-ESRD subjects. Here, the P value of the two-SNP (AG) risk haplotype improved to 0.0008 (odds ratio 1.51), while the four-SNP (GAGA) protective haplotype was similar to the control versus DM-ESRD comparison (P = 0.0056, odds ratio 0.37). Taken together, these analyses tend to support a genetic association with diabetes rather than diabetic nephropathy.
###end p 41
###begin p 42
###xml 112 118 112 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 200 201 200 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 616 617 616 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 744 750 744 750 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 852 858 852 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 926 932 926 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 1058 1059 1054 1055 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
To determine whether either of these disease-associated haplotypes correlated with general expression levels of ENTPD1, we took advantage of the fact that ENTPD1 is highly expressed on B-lymphocytes (6). For the two-SNP haplotype, we examined YRI Hapmap lymphoblasts for subjects who were homozygous for the three different haplotype groups. While many subjects in the YRI population were homozygous for the AG risk haplotype, only two were homozygous for the AA protective haplotype and only one was homozygous for the TG protective haplotype. Since the AA and TG haplotypes were almost identical in terms of risk (P = 0.04, nominally protective) and odds ratios (0.70 and 0.64, respectively), we pooled these into a single group and compared ENTPD1 expression from their lymphocytes with those from the risk (AG) haplotype group using real-time PCR (Fig. 1A). Lymphocytes homozygous for the AG risk haplotype had 39% higher ENTPD1 expression levels than homozyogotes for the protective AA or TG haplotypes (protective 5.62 +/- 0.36 vs. risk 7.81 +/- 0.36; P = 0.007), with no overlap between groups (range 5.09-6.30 for protective and 6.91-9.53 for risk). Not enough cell lines homozygous for the four-SNP protective haplotype (one cell line) were available for comparison.
###end p 42
###begin p 43
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 3 9 3 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 121 122 121 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 172 173 172 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 211 217 211 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 342 343 342 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 355 361 355 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 403 404 403 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 430 431 430 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 564 570 564 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 583 584 583 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 586 592 586 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 634 635 634 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 661 662 661 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 792 798 792 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 930 931 930 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 1143 1144 1143 1144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1164 1170 1164 1170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 1235 1236 1235 1236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1244 1245 1244 1245 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</italic>
###xml 1261 1267 1261 1267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 1324 1325 1324 1325 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1370 1371 1370 1371 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
A: ENTPD1 mRNA expression by real-time PCR comparing YRI Hapmap cell lines homozygous for the two-SNP risk haplotype AG (n = 7) versus the protective haplotypes AA and TG (n = 3), normalized for 18S expression. ENTPD1 mRNA levels are 39% higher in cell lines with zero protective haplotypes than in cell lines with two protective haplotypes. B: In silico ENTPD1 expression for YRI cell lines with zero (n = 31) versus one or two (n = 29) copies of the two-SNP protective haplotypes AA and TG. Zero copies of the protective haplotype conferred 16% higher levels of ENTPD1 expression. C: ENTPD1 expression for YRI cell lines with zero (n = 53) versus one or two (n = 7) copies of the four-SNP protective (GAGA) haplotype. Zero copies of the protective haplotype were associated with 16% higher ENTPD1 expression. Though nonsignificant, cell lines with one or two protective copies had lower expression than all other groups tested. D: Protective index incorporating both the two- and four-SNP haplotypes. The total number of protective two- and four-SNP protective alleles was summed for each cell line. Cell lines with zero protective alleles (n = 29) had 18% more ENTPD1 expression than cell lines with at least one protective allele (n = 31). E: Comparison of ENTPD1 mRNA expression of protective four-SNP haplotype (GAGA, n = 7) and uncommon four-SNP haplotype (GTGA, n = 3) that share the minor allele (A) at rs3793744 that codes for a valine to isoleucine substitution at amino acid 293. The difference indicates that rs3793744 is not itself the causal SNP.
###end p 43
###begin p 44
###xml 138 140 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 559 560 559 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 586 592 586 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 646 647 646 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 654 655 654 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 666 672 666 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 672 673 672 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 758 759 758 759 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 810 811 810 811 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 861 862 861 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 924 930 924 930 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 978 984 978 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 984 985 984 985 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 1538 1544 1538 1544 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 1591 1592 1591 1592 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1618 1624 1618 1624 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 1718 1719 1718 1719 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1727 1728 1727 1728 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
To provide additonal support for a correlation between haplotype and expression level, we used gene expression data from Stranger et al. (18) generated from YRI HapMap cell lines, which allowed us to incorporate haplotype heterozygotes into the analysis. For consistency, we analyze the two- and four-SNP haplotypes in terms of number of protective alleles. We pooled subjects with one or two protective alleles for the two-SNP haplotype and compared them with subjects with no protective alleles (two risk alleles). Subjects with zero protective haplotypes (n = 31) expressed 16% more ENTPD1 than subjects with one or two protective haplotypes (n = 29; P = 0.027) (Fig. 1B). We then pooled subjects with one or two copies of the protective four-SNP allele (n = 7) and compared them with those with no copies (n = 53). While the difference was not significant (P = 0.09), those with no protective alleles expressed 16% more ENTPD1 than those with one or two protective alleles (Fig. 1C). These cell lines with at least one protective four-SNP allele had the lowest mRNA expression levels of any haplotype group, including the protective two-SNP haplotype. To account for the fact that we were comparing subjects with protective four-SNP alleles versus a pool that contained many more subjects with one or more protective two-SNP allele, we then compared subjects based on their total number of protective alleles (two-SNP protective alleles plus four-SNP protective alleles) to integrate the effects of two-SNP and four-SNP haplotypes on ENTPD1 expression. Those with no protective alleles (n = 29) expressed 18% more ENTPD1 than subjects with at least one protective two-SNP allele or one protective four-SNP allele (n = 31) (P = 0.01). Both haplotypes appear to correlate with ENTPD1 expression and were especially predictive of mRNA expression levels when used in tandem. The small number of subjects with the protective four-SNP allele prevented us from determining whether the effects of the two-SNP and four-SNP haplotypes were independent.
###end p 44
###begin p 45
###xml 496 502 496 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 583 584 583 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 593 594 593 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 600 601 600 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 933 934 933 934 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 939 940 939 940 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 1206 1207 1206 1207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 1212 1213 1212 1213 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
The protective four-SNP haplotype (GAGA) included a SNP causing an amino acid change (rs3793744: V to I at position 293). A second, uncommon haplotype (GTGA) also included the minor allele (A) at rs3793744 but was not associated with DM-ESRD when compared with control subjects. We compared expression levels between cell lines with one or more copies of each of these haplotypes. Remarkably, the nonprotective (GTGA) four-SNP haplotype including the minor allele at rs3793744 expressed 45% more ENTPD1 mRNA than the protective (GAGA) four-SNP allele with the same SNP at rs3793744 (n = 3 vs. n = 7, P = 0.0006). This finding suggests that differences in mRNA expression underly the effect of the four-SNP haplotype rather than the amino acid substitution. We did note, though, that protein expression in the homozygotes for the protective four-SNP haplotype were surprisingly low compared with other cell lines (supplementary Fig. 1A and B). This finding was demonstrated in single samples from two separate collections (HapMap and Perlegen), and activity assays showed that the effect was not due to differential antibody binding at the amino acid change at position 293 (rs3793744) (supplementary Fig. 1C and D).
###end p 45
###begin p 46
###xml 38 44 38 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 100 106 100 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 122 127 122 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">db/db</italic>
###xml 300 306 300 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 421 422 415 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 483 489 477 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 489 490 483 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 495 496 489 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 609 614 603 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">db/db</italic>
###xml 637 643 631 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 645 651 639 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 651 654 645 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C&#8211;E</italic>
###xml 112 116 <span type="species:ncbi:10090">mice</span>
###xml 128 132 <span type="species:ncbi:10090">mice</span>
###xml 287 291 <span type="species:ncbi:10090">mice</span>
###xml 615 619 <span type="species:ncbi:10090">mice</span>
To further investigate the effects of ENTPD1 on either diabetes or diabetic nephropathy, we crossed ENTPD1-null mice with db/db mice to create a type 2 model of diabetes and type 2 diabetic nephropathy. Assessment for renal injury at 8 months of age demonstrated that in the nondiabetic mice (db/-), ENTPD1 deletion caused mildly increased albuminuria (wild type = 37.2 +/- 2.3 mug/mg vs. knockout = 54.7 +/- 6.7 mug/mg; P = 0.028) and a trend toward increased glomerular sclerosis (Fig. 2A and B). In the diabetic groups, there were no differences in albuminuria, sclerosis index, or glomerular area between db/db mice with and without ENTPD1 (Fig. 2C-E).
###end p 46
###begin p 47
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 58 59 58 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 68 74 68 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 89 90 89 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 100 106 100 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 117 118 117 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 163 164 163 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 173 179 173 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 194 195 194 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 205 211 205 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 222 223 222 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 257 262 257 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">db/db</italic>
###xml 269 270 269 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 280 286 280 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 301 302 301 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 311 317 311 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 328 329 328 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 351 356 351 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">db/db</italic>
###xml 363 364 363 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 374 380 374 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 395 396 395 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 406 412 406 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 423 424 423 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</italic>
###xml 446 451 446 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">db/db</italic>
###xml 458 459 458 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 469 475 469 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 490 491 490 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 500 506 500 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 52 56 <span type="species:ncbi:10090">mice</span>
###xml 157 161 <span type="species:ncbi:10090">mice</span>
###xml 263 267 <span type="species:ncbi:10090">mice</span>
###xml 357 361 <span type="species:ncbi:10090">mice</span>
###xml 452 456 <span type="species:ncbi:10090">mice</span>
A: Albumin-to-creatinine ratio for db/- nondiabetic mice. n = 7 for ENTPD1 wild type and n = 12 for ENTPD1 knockout. B: Sclerosis index for db/- nondiabetic mice. n = 7 for ENTPD1 wild type and n = 12 for ENTPD1 knockout. C: Albumin-to-creatinine ratio for db/db mice. n = 13 for ENTPD1 wild type and n = 9 for ENTPD1 knockout. D: Sclerosis index for db/db mice. n = 13 for ENTPD1 wild type and n = 10 for ENTPD1 knockout. E: Glomerular area for db/db mice. n = 10 for ENTPD1 wild type and n = 8 for ENTPD1 knockout.
###end p 47
###begin p 48
###xml 104 108 104 108 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p.m.</sc>
###xml 131 137 131 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 233 234 229 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 326 327 318 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 338 344 330 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 344 345 336 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 350 351 342 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 404 409 396 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">db/db</italic>
###xml 454 460 446 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 462 468 454 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 468 469 460 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 474 475 466 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 531 537 523 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4</xref>
###xml 537 538 529 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 543 544 535 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 578 583 570 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">db/db</italic>
###xml 607 613 599 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 648 653 640 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">db/db</italic>
###xml 734 735 722 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 817 818 801 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 832 838 816 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4</xref>
###xml 838 839 822 823 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 844 845 828 829 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 81 85 <span type="species:ncbi:10090">mice</span>
###xml 143 147 <span type="species:ncbi:10090">mice</span>
###xml 507 511 <span type="species:ncbi:10090">mice</span>
###xml 584 588 <span type="species:ncbi:10090">mice</span>
###xml 654 658 <span type="species:ncbi:10090">mice</span>
Metabolic syndrome parameters revealed more dramatic differences. In nondiabetic mice, nonfasting (3:00 p.m.) glucose was lower in ENTPD1-null mice at both 8 weeks (wild type = 208.1 +/- 4.8 mg/dl vs. knockout = 176.8 +/- 7.8 mg/dl; P = 0.006) and 6 months (wild type = 179.2 +/- 5.7 mg/dl vs. knockout = 161.9 +/- 5.8 mg/dl; P = 0.039) (Fig. 3A and B). No differences in glucose levels were seen in the db/db groups at these time points with or without ENTPD1 (Fig. 3C and D). While weights of nondiabetic mice were no different (Fig. 4A and B), large differences were seen in db/db mice, with deletion of ENTPD1 protecting against obesity in the db/db mice at both 8 weeks (wild type = 41.4 +/- 1.0 g vs. knockout = 37.6 +/- 1.4 g; P = 0.026) and 6 months (wild type = 62.4 +/- 0.9 g vs. knockout = 52.0 +/- 1.3 g; P < 0.000001) (Fig. 4C and D).
###end p 48
###begin p 49
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 6 7 6 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 68 69 68 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 85 86 85 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 89 90 89 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 99 105 99 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 120 121 120 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 131 137 131 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 148 149 148 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 154 155 154 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 182 187 182 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">db/db</italic>
###xml 205 206 205 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 222 223 222 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 226 227 226 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 240 246 240 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 261 262 261 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 275 281 275 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 51 55 <span type="species:ncbi:10090">mice</span>
###xml 188 192 <span type="species:ncbi:10090">mice</span>
A and B: Blood glucose levels for db/- nondiabetic mice at 8 weeks (A) and 6 months (B). n = 9 for ENTPD1 wild type and n = 12 for ENTPD1 knockout. C and D: Blood glucose levels for db/db mice at 8 weeks (C) and 6 months (D). n = 19-20 for ENTPD1 wild type and n = 12-13 for ENTPD1 knockout.
###end p 49
###begin p 50
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 6 7 6 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 55 56 55 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 72 73 72 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 76 77 76 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 86 92 86 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 107 108 107 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 118 124 118 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 135 136 135 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 141 142 141 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 156 161 156 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">db/db</italic>
###xml 179 180 179 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 196 197 196 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 200 201 200 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 214 220 214 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 235 236 235 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 249 255 249 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 38 42 <span type="species:ncbi:10090">mice</span>
###xml 162 166 <span type="species:ncbi:10090">mice</span>
A and B: Weights for db/- nondiabetic mice at 8 weeks (A) and 6 months (B). n = 9 for ENTPD1 wild type and n = 12 for ENTPD1 knockout. C and D: Weights for db/db mice at 8 weeks (C) and 6 months (D). n = 19-20 for ENTPD1 wild type and n = 13-15 for ENTPD1 knockout.
###end p 50
###begin p 51
###xml 27 33 27 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 144 149 144 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">db/db</italic>
###xml 176 182 176 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 298 299 294 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 385 386 377 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 421 427 413 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Fig. 5</xref>
###xml 427 428 419 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 433 434 425 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 39 43 <span type="species:ncbi:10090">mice</span>
###xml 188 192 <span type="species:ncbi:10090">mice</span>
###xml 532 536 <span type="species:ncbi:10090">mice</span>
We also aged wild-type and ENTPD1-null mice (leptin receptor normal) to see if aging would cause similar metabolic differences as we saw in the db/db model. At 2 years of age, ENTPD1-null mice had markedly lower fasting glucoses (wild type = 141.6 +/- 5.1 mg/dl vs. knockout = 112.8 +/- 3.3 mg/dl; P = 0.0009) and lower weights (wild type = 46.4 +/- 2.7 g vs. knockout = 39.2 +/- 0.7; P = 0.042) than wild type controls (Fig. 5A and B). Consistent with the db experiments, we did also note increased albuminuria in aged ENTPD1-null mice despite lower weights and blood glucoses (D.J.F., unpublished data).
###end p 51
###begin p 52
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 61 62 61 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 72 78 72 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 85 86 85 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 98 99 98 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 133 134 133 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 144 150 144 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 157 158 157 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 92 96 <span type="species:ncbi:10090">mice</span>
###xml 165 169 <span type="species:ncbi:10090">mice</span>
A: Fasting glucose levels in mg/dl for 2-year-old wild-type (n = 8) and ENTPD1-null (n = 6) mice. B: Weight at 2 years in wild-type (n = 7) and ENTPD1-null (n = 11) mice.
###end p 52
###begin title 53
DISCUSSION
###end title 53
###begin p 54
###xml 24 30 24 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 184 190 184 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 548 549 548 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 889 890 889 890 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 36 40 <span type="species:ncbi:10090">mice</span>
###xml 199 205 <span type="species:ncbi:9606">humans</span>
Our previous studies in ENTPD1-null mice suggested a role for this ectonucleotidase in both resistance to renal injury and in glucose homeostasis. We tested polymorphic markers in the ENTPD1 gene in humans for association with diabetic ESRD and nondiabetic ESRD in African Americans, a group of Americans with high rates of both diseases. We found two common polymorphisms (rs12763743 and rs3897983) that are nominally associated with diabetic but not nondiabetic ESRD. When used together, these two polymorphisms showed even stronger association (P = 0.0027) with subjects in the diabetic nephropathy group. These two SNPs may represent independent, additive effects or they may together tag a causal SNP better than either of the SNPs alone. More general haplotype analysis also identified an uncommon four-SNP haplotype that appears to protect against diabetes or diabetic nephropathy (P = 0.004). The effect size of this uncommon haplotype is strong, conferring a relative risk of 0.34. Additional groupwise comparisons using pooled groups further suggested that the association was due to diabetes rather than nephropathy in the DM-ESRD groups.
###end p 54
###begin p 55
###xml 42 48 42 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 154 160 154 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 594 600 594 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 841 847 841 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
To support association the association of ENTPD1 with diabetes and/or diabetic nephropathy, we tested HapMap cell lines derived from African subjects for ENTPD1 expression. Cell lines homozygous for the two-SNP (AG) risk haplotype expressed 39% more ENTPD1 mRNA than those cell lines with two protective haplotypes (AA and TG). We performed additional bioinformatic analysis that showed similar results: zero alleles of the two-SNP protective haplotypes led to 16% greater ENTPD1 expression than one or two protective alleles. The protective four-SNP haplotype also showed a trend toward lower ENTPD1 expression levels, though this analysis was limited by fewer representative cell lines and was confounded by comparison with a group including many protective two-SNP haplotypes. In fact, the protective four-SNP haplotype showed the lowest ENTPD1 expression of any group. By using an index that took into account the total number of both the two- and four-SNP protective haplotypes, we identified a strong correlation between genotype and ENTPD1 mRNA expression level using both haplotypes derived from our genetic association study. Additional experiments measuring ENTPD1 protein levels confirmed that the protective four-SNP haplotype was associated with very low ENTPD1 levels and may suggest an effect beyond mRNA expression, though we did not have sufficient samples available to us to prove this hypothesis definitively.
###end p 55
###begin p 56
###xml 59 65 59 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 110 116 110 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 284 290 284 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 359 364 359 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">db/db</italic>
###xml 428 433 428 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">db/db</italic>
###xml 485 491 485 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 549 551 549 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 724 729 724 729 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">db/db</italic>
###xml 1111 1117 1111 1117 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 32 36 <span type="species:ncbi:10090">mice</span>
###xml 130 134 <span type="species:ncbi:10090">mice</span>
###xml 190 194 <span type="species:ncbi:10090">mice</span>
###xml 296 300 <span type="species:ncbi:10090">mice</span>
###xml 497 501 <span type="species:ncbi:10090">mice</span>
###xml 543 547 <span type="species:ncbi:10090">mice</span>
###xml 739 743 <span type="species:ncbi:10090">mice</span>
###xml 878 882 <span type="species:ncbi:10090">mice</span>
###xml 1024 1029 <span type="species:ncbi:10090">mouse</span>
###xml 1086 1092 <span type="species:ncbi:9606">humans</span>
###xml 1225 1229 <span type="species:ncbi:10090">mice</span>
We also used genetic studies in mice to assess the role of ENTPD1 on diabetes and diabetic nephropathy. While ENTPD1-null control mice did have increased albuminuria compared with wild-type mice, perhaps the more striking findings related to metabolic syndrome traits. In particular, ENTPD1-null mice had lower glucose levels in the absence of the homozygous db/db mutation and dramatically lower weights in the presence of the db/db mutation. Notably, previous work demonstrated that ENTPD1-null mice have higher leptin levels than wild-type mice (13), potentially a compensatory response that is disabled in the absence of one or both copies of the normal leptin receptor. The exact reason for this differential effect in db/db and db/- mice on blood glucose and weight still remains to be elucidated. However, even in the presence of normal leptin signaling, using wild-type mice rather than db/- heterozygotes as controls, aging accentuated both phenotypes (i.e., difference in glucose homeostasis and weight gain). Our mouse findings again suggest that the effect we discovered in humans may relate to low ENTPD1 protecting against diabetes in control subjects, though increased albuminuria in the nondiabetic CD39-null mice may point toward an effect on renal disease as well.
###end p 56
###begin p 57
###xml 40 46 40 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 194 199 194 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENPP1</italic>
###xml 309 314 309 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENPP1</italic>
###xml 362 364 362 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 364 364 364 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21"/>
###xml 365 367 365 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 449 451 449 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 548 550 548 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 642 644 642 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 645 647 645 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 670 676 670 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD1</italic>
###xml 680 684 <span type="species:ncbi:10090">mice</span>
Further support for association between ENTPD1 and diabetes and diabetic nephropathy is the finding that polymorphisms in another ectonucleotidase with a remarkably similar enzymatic mechanism, ENPP1, have also been associated with both diabetes and diabetic nephropathy. Nephropathy has been associated with ENPP1 polymorphisms, first in Caucasian populations (20-22), and subsequently in an African American population that included our subjects (23). Polymorphisms in the same gene also have an important influence on metabolic syndrome traits (14), and there appears to be an important interaction between weight and glucose homeostasis (24,25), just as we see with ENTPD1 in mice. While ENPP1 hydrolyzes extracellular ATP to AMP and pyrophosphate, ENTPD1 hydrolyzes extracellular ATP to AMP and two phosphate molecules. Low functional expression of either of these ectoenzymes could increase extracellular levels of ATP and decrease levels of the nucleoside adenosine.
###end p 57
###begin p 58
###xml 426 431 426 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENPP1</italic>
###xml 94 99 <span type="species:ncbi:9606">human</span>
###xml 215 220 <span type="species:ncbi:10090">mouse</span>
The strength of our study rests on mutually supportive data built from genetic association of human disease with genetic variants, gene expression levels that correlate with the disease-associated haplotypes, and a mouse model that shows phenotypic differences based on expression level of the gene. Ultimately, replication in larger cohorts will be needed to validate our findings. Our data, along with previous studies with ENPP1, suggest that extracellular nucleotide metabolism may be a critical determinant of diabetes and/or diabetic nephropathy.
###end p 58
###begin title 59
Supplementary Material
###end title 59
###begin title 60
Online-Only Appendix
###end title 60
###begin p 61
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 61
###begin title 62
Acknowledgments
###end title 62
###begin p 63
###xml 181 186 <span type="species:ncbi:9606">Human</span>
###xml 249 254 <span type="species:ncbi:9606">human</span>
This work was supported by National Institutes of Health grants K08-DK-076868 (to D.J.F.) and P01 HL-076540 (to S.C.R). We acknowledge Coriell Institute, Perlegen, and the National Human Genome Research Institute (NHGRI) for their role in providing human cell lines to the research community.
###end p 63
###begin p 64
No potential conflicts of interest relevant to this article were reported.
###end p 64
###begin p 65
We thank Barbara Stranger, Emmanouil Dermitzakis, and their colleagues for making their gene expression data publicly available.
###end p 65
###begin title 66
REFERENCES
###end title 66
###begin article-title 67
Genetic factors in end-stage renal disease.
###end article-title 67
###begin article-title 68
Genetic factors in diabetic nephropathy.
###end article-title 68
###begin article-title 69
The inherited basis of diabetes mellitus: implications for the genetic analysis of complex traits.
###end article-title 69
###begin article-title 70
###xml 61 67 <span type="species:ncbi:10090">murine</span>
Differential catalytic properties and vascular topography of murine nucleoside triphosphate diphosphohydrolase 1 (NTPDase1) and NTPDase2 have implications for thromboregulation.
###end article-title 70
###begin article-title 71
The CD39 lymphoid cell activation antigen. Molecular cloning and structural characterization.
###end article-title 71
###begin article-title 72
CD39 is the dominant Langerhans cell-associated ecto-NTPDase: modulatory roles in inflammation and immune responsiveness.
###end article-title 72
###begin article-title 73
###xml 39 45 <span type="species:ncbi:10090">murine</span>
Expression of NTPDase1 and NTPDase2 in murine kidney: relevance to regulation of P2 receptor signaling.
###end article-title 73
###begin article-title 74
The vascular ectonucleotidase ENTPD1 is a novel renoprotective factor in diabetic nephropathy.
###end article-title 74
###begin article-title 75
Contribution of E-NTPDase1 (CD39) to renal protection from ischemia-reperfusion injury.
###end article-title 75
###begin article-title 76
###xml 52 57 <span type="species:ncbi:9606">human</span>
Linkage heterogeneity of end-stage renal disease on human chromosome 10.
###end article-title 76
###begin article-title 77
A genome-wide linkage scan for genes controlling variation in renal function estimated by serum cystatin C levels in extended families with type 2 diabetes.
###end article-title 77
###begin article-title 78
Deletion of Cd39/Entpd1 results in hepatic insulin resistance.
###end article-title 78
###begin article-title 79
Variants of ENPP1 are associated with childhood and adult obesity and increase the risk of glucose intolerance and type 2 diabetes.
###end article-title 79
###begin article-title 80
Variants of the transcription factor 7-like 2 (TCF7L2) gene are associated with type 2 diabetes in an African-American population enriched for nephropathy.
###end article-title 80
###begin article-title 81
A genome scan for all-cause end-stage renal disease in African Americans.
###end article-title 81
###begin article-title 82
SNP genotyping using Sequenom MassARRAY 7K platform.
###end article-title 82
###begin article-title 83
###xml 23 28 <span type="species:ncbi:9606">human</span>
Population genomics of human gene expression.
###end article-title 83
###begin article-title 84
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression.
###end article-title 84
###begin article-title 85
###xml 102 110 <span type="species:ncbi:9606">patients</span>
PC-1 amino acid variant Q121 is associated with a lower glomerular filtration rate in type 2 diabetic patients with abnormal albumin excretion rates.
###end article-title 85
###begin article-title 86
Polymorphism in ecto-nucleotide pyrophosphatase/phosphodiesterase 1 gene (ENPP1/PC-1) and early development of advanced diabetic nephropathy in type 1 diabetes.
###end article-title 86
###begin article-title 87
###xml 92 100 <span type="species:ncbi:9606">patients</span>
A PC-1 amino acid variant (K121Q) is associated with faster progression of renal disease in patients with type 1 diabetes and albuminuria.
###end article-title 87
###begin article-title 88
Association of the distal region of the Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) gene with type 2 diabetes in an African American population enriched for nephropathy.
###end article-title 88
###begin article-title 89
The ENPP1 K121Q polymorphism is associated with type 2 diabetes in European populations: evidence from an updated meta-analysis in 42,042 subjects.
###end article-title 89
###begin article-title 90
Haplotype structure of the ENPP1 Gene and Nominal Association of the K121Q missense single nucleotide polymorphism with glycemic traits in the Framingham Heart Study.
###end article-title 90

